Tianjin Huairen Pharmaceutical Co., Ltd. was founded in 2002 and is located in Xiqing Economic Development Zone of Tianjin. It is a modern pharmaceutical enterprise integrating scientific research, production and sales. It is now a high-tech pharmaceutical enterprise and technology recognized by Tianjin Science and Technology Commission. Small and medium-sized enterprises. There are 6 shareholders including Haina Sunshine (Beijing) Pharmaceutical Holdings Co., Ltd., Tianjin Science and Technology Investment Group Co., Ltd., Institute of Hematology, Chinese Academy of Medical Sciences. Since its establishment, the company has been adhering to the business philosophy of "quality first, reputation first". In the past years, the market sampling inspection rate has reached 100%, and it has been praised by the Tianjin Market and Quality Supervision and Administration Commission as "A-level enterprise for quantitative production and classification management of pharmaceutical production" and "Reassuring Pharmaceutical Factory" for many consecutive years. In 2014, it successfully passed the new version of GMP certification.
Since its development, the company has mainly produced APIs, tablets, capsules, granules and other dosage forms. There are more than 10 products including gliclazide sustained-release tablets, iron dextran tablets, iron dextran raw materials, telmisartan tablets, simvastatin tablets, irbesartan hydrochlorothiazide dispersible tablets and so on. Among them, dextran iron tablets have the advantages of self-produced raw materials and multiple specifications among similar domestic manufacturers. Sales have steadily increased and are in the forefront for ten years. Telmisartan tablets are currently the company's largest-selling products. Over the years, they have accumulated loyal drug users and have performed well among pharmaceutical companies of the same size.
In order to achieve faster and better development of the company, Huairen Pharmaceutical is committed to introducing strong strategic investors. In 2013, Haina Sunshine successfully invested in the company and became the largest shareholder of Huairen Company through equity transfer in early 2018. The restructured Huairen Company will integrate resources, strengthen technological and management innovation, break through bottlenecks, and achieve steady development of the enterprise.
CN
